Immune checkpoint inhibitors (ICIs) are pivotal in managing metastatic non-oncogene addicted non-small-cell lung cancer (NSCLC). They have unique toxicities known as immune-related adverse events (irAEs). Previous studies have linked irAEs during atezolizumab-based first-line treatments in advanced NSCLC with improved outcomes. This study explored the association between irAEs and the efficacy of atezolizumab in advanced NSCLC patients who had previously received platinum-based chemotherapy. The study involved 105 advanced NSCLC patients who received atezolizumab monotherapy after progressing on at least one line of platinum-based chemotherapy from a single academic institution in Serbia. Data were obtained from a hospital lung cancer registry. Among the participants, 63.8% were male, with the majority being current (53.3%) or former smokers (37.1%). About half had a good performance status (ECOG PS 0–1) at the start of atezolizumab treatment. irAEs occurred in 23 patients (21.9%). The median progression-free survival (mPFS) was significantly longer for patients with irAEs (13.03 months) compared to those without (3.4 months) (HR 0.365 [95% CI, 0.195–0.681],p= 0.002). irAEs and ECOG PS 0–1 were predictors of longer mPFS, with irAEs being more common in patients with good performance status (p= 0.01). irAEs were linked to improved mPFS in NSCLC patients treated with atezolizumab after multiple lines of platinum-based chemotherapy.
免疫检查点抑制剂（ICIs）在治疗转移性非致癌基因依赖型非小细胞肺癌（NSCLC）中具有关键作用。这类药物具有独特的毒性，称为免疫相关不良事件（irAEs）。既往研究表明，在晚期NSCLC患者中，基于阿特珠单抗的一线治疗期间发生的irAEs与改善的临床结局相关。本研究探讨了irAEs与阿特珠单抗在既往接受过铂类化疗的晚期NSCLC患者中的疗效关联。研究纳入了来自塞尔维亚一家学术机构的105例晚期NSCLC患者，这些患者在至少一线铂类化疗进展后接受了阿特珠单抗单药治疗。数据来源于医院肺癌登记系统。参与者中63.8%为男性，大多数为当前吸烟者（53.3%）或既往吸烟者（37.1%）。约半数患者在开始阿特珠单抗治疗时体能状态良好（ECOG PS 0-1）。23例患者（21.9%）发生了irAEs。与未发生irAEs的患者相比，发生irAEs患者的中位无进展生存期（mPFS）显著延长（13.03个月 vs. 3.4个月）（HR 0.365 [95% CI, 0.195–0.681], p=0.002）。irAEs和ECOG PS 0-1是较长mPFS的预测因素，且irAEs在体能状态良好的患者中更为常见（p=0.01）。在接受多线铂类化疗后使用阿特珠单抗治疗的NSCLC患者中，irAEs与改善的mPFS相关。
肿瘤(癌症)患者之家